The status and progress of first-line treatment against <i>Helicobacter pylori</i> infection: a review.

Liu, Caiqi; Wang, Yuan; Shi, Jiaqi; Zhang, Chunhui; Nie, Jianhua; Li, Shun; Zheng, Tongsen

The status and progress of first-line treatment against Helicobacter pylori infection: a review.

Liu, Caiqi; Wang, Yuan; Shi, Jiaqi; Zhang, Chunhui; Nie, Jianhua; Li, Shun; Zheng, Tongsen.

Afiliação

Liu C; Harbin Medical University, Harbin, China.
Wang Y; Harbin Medical University, Harbin, China.
Shi J; Harbin Medical University, Harbin, China.
Zhang C; Harbin Medical University, Harbin, China.
Nie J; Harbin Medical University, Harbin, China.
Li S; Harbin Medical University, Harbin, China.
Zheng T; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital; Key Laboratories of Molecular Oncology of Heilongjiang Province, No.150 Haping Road, Nangang District, Harbin, China.

Therap Adv Gastroenterol ; 14: 1756284821989177, 2021.

Article em En | MEDLINE | ID: mdl-34262609

Palavras-chave

Helicobacter pylori; drug resistance; first-line therapy; quadruple therapy; triple therapy; vonoprazan

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Therap Adv Gastroenterol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google